Business
India
India
Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?
Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady r…
Continue Reading on Economic Times - Markets
This article is aggregated from Economic Times - Markets. Click below to read the full story.
Economic Times
Bloomberg